NCT03763877 - A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD | Crick | Crick

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Phase 2CompletedNCT03763877

Poxel SA121 enrolled

Overview

This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.

The study will be performed in patients with Nonalcoholic Fatty Liver Disease. The primary endpoint will be the assessment of the change in the percentage of liver fat mass (assessed by MRI-PDFF).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

121

Conditions

Nonalcoholic Fatty Liver

Interventions

Oral capsule

Placebo Oral CapsuleDRUG

Oral capsule

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients have given written informed consent * Body mass index (BMI) ≥ 25 to ≤ 50 kg/m² * For patients with type 2 diabetes mellitus: either naive of glucose lowering drug or under stable oral glucose lowering drug * Estimated glomerular filtration rate (eGFR) ≥ 60 mL/\[min\*1.73m²\] * Alanine amino transferase (ALT) \> 20 IU/L in females and \> 30 IU/L in males * Hepatic steatosis (MRI-PDFF ≥ 10%) * Effective contraception for women of child bearing potential Exclusion Criteria: * Evidence of another form of liver disease * Evidence of liver cirrhosis * Evidence of hepatic impairment * Positive serologic evidence of current infectious liver disease * History of excessive alcohol intake * Acute cardiovascular disease with 24 weeks prior to screening * Uncontrolled high blood pressure * Any disease which in the Investigator's opinion which in the Investigator's opinion would exclude the patient from the study * Use of non-permitted concomitant medication * Pregnancy or lactation

Locations (15)

Study Site 02

Los Angeles, California, United States

Study Site 01

Gainesville, Florida, United States

Study Site 11

Ocoee, Florida, United States

Outcomes

Primary Outcomes

Relative Change in the Percentage of Liver Fat Mass (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF]) From Baseline to Week 12/End of Treatment (EOT)

MRI acquisitions were performed at pre-qualified local MRI facilities using qualified and standardized instruments at high field strength (3 T or 1.5T) without oral or intravenous contrast. All acquisitions images were transferred to a central reader vendor for central calculation and measurement of MRI-PDFF using the method of Zhong et al. to estimate water and fat components. A 3 cm2 region of interest (ROI) was placed in each Couinaud segment. Central reading was masked to treatment group, clinical data, study site of origin and timepoint.

Time frame: Baseline to Week 12

Relative Change in the Percentage of Liver Fat Mass (Assessed by MRI-PDFF) From Baseline to Week 12/End of Treatment (Per Protocol Sensitivity Analysis)

MRI acquisitions were performed at pre-qualified local MRI facilities using qualified and standardized instruments at high field strength (3 T or 1.5T) without oral or intravenous contrast. All acquisitions images were transferred to a central reader vendor for central calculation and measurement of MRI-PDFF using the method of Zhong et al. to estimate water and fat components. A 3 cm2 ROI was placed in each Couinaud segment. Central reading was masked to treatment group, clinical data, study site of origin and timepoint.

Time frame: Baseline to Week 12

Relative Change in the Percentage of Liver Fat Mass (Assessed by MRI-PDFF) From Baseline to Week 12/End of Treatment (Unstratified Wilcoxon Sensitivity Analysis)

MRI acquisitions were performed at pre-qualified local MRI facilities using qualified and standardized instruments at high field strength (3 T or 1.5T) without oral or intravenous contrast. All acquisitions images were transferred to a central reader vendor for central calculation and measurement of MRI-PDFF using the method of Zhong et al. to estimate water and fat components. A 3 cm2 ROI was placed in each Couinaud segment. Central reading was masked to treatment group, clinical data, study site of origin and timepoint.

Time frame: Baseline to Week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Absolute Change in the Percentage of Liver Fat Mass (Assessed by MRI-PDFF) From Baseline to Week 12/End of Treatment

MRI acquisitions were performed at pre-qualified local MRI facilities using qualified and standardized instruments at high field strength (3 T or 1.5T) without oral or intravenous contrast. All acquisitions images were transferred to a central reader vendor for central calculation and measurement of MRI-PDFF using the method of Zhong et al. to estimate water and fat components. A 3 cm2 ROI was placed in each Couinaud segment. Central reading was masked to treatment group, clinical data, study site of origin and timepoint.

Time frame: Baseline to Week 12

Percentage of Responders (Relative Reduction of at Least 30% in Liver Fat Mass) at Week 12/End of Treatment

Responders were defined as patients who achieved a clinically meaningful relative reduction of at least 30% in liver fat mass From baseline to Week 12/EOT as assessed by MRI-PDFF

Time frame: Baseline to Week 12

Change in Alanine Amino Transferase (ALT) From Baseline to Week 12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Aspartate Amino Transferase (AST) From Baseline to Week 12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Fasting Plasma Glucose (FPG) From Baseline to Week12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Glycated Hemoglobin (HbA1c) From Baseline to Week12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Total Cholesterol From Baseline to Week12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in High Density Lipoprotein-Cholesterol (HDL-C) From Baseline to Week12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Week12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Triglycerides From Baseline to Week12/End of Treatment

Blood samples were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Fibrosis-4 (Fib-4) Score From Baseline to Week 12/End of Treatment

Fib-4 score is a non invasive method based on clinical determinations that indicates the level of fibrosis/ scarring of the liver. The set cutoffs for this scoring are: Fib-4 \< 1.45: absence of cirrhosis; Fib-4 between 1.45 - 3.25: inconclusive and Fib-4 \> 3.25: cirrhosis. Fib-4 score was calculated as (Age \[years\] × AST \[U/L\]) / (platelet \[10\^9/L\] × √\[ALT \[U/L\]\]). Blood samples used for AST, ALT and platelet counts were collected, handled and stored according to the instructions described in the laboratory manual and all measurements were performed at a central laboratory.

Time frame: Baseline to Week 12

Change in Body Weight From Baseline to Week 12/End of Treatment

Body weight was measured using a scale with appropriate resolution, placed on a stable, flat surface. Shoes, bulky layers of clothing, and jackets had to be removed so that only light clothing remained.

Time frame: Baseline to Week 12